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ABSTRACT
Objectives: Data on costs associated with acute
upper gastrointestinal bleeding (AUGIB) are scarce. We
provide estimates of UK healthcare costs, indirect costs
and health-related quality of life (HRQoL) for patients
presenting to hospital with AUGIB.
Setting: Six UK university hospitals with >20 AUGIB
admissions per month, >400 adult beds, 24 h
endoscopy, and on-site access to intensive care and
surgery.
Participants: 936 patients aged ≥18 years, admitted
with AUGIB, and enrolled between August 2012 and
March 2013 in the TRIGGER trial of AUGIB comparing
restrictive versus liberal red blood cell (RBC)
transfusion thresholds.
Primary and secondary outcome measures:
Healthcare resource use during hospitalisation and
postdischarge up to 28 days, unpaid informal care,
time away from paid employment and HRQoL using
the EuroQol EQ-5D at 28 days were measured
prospectively. National unit costs were used to value
resource use. Initial in-hospital treatment costs were
upscaled to a UK level.
Results: Mean initial in-hospital costs were £2458
(SE=£216) per patient. Inpatient bed days, endoscopy
and RBC transfusions were key cost drivers.
Postdischarge healthcare costs were £391 (£44) per
patient. One-third of patients received unpaid informal
care and the quarter in paid employment required time
away from work. Mean HRQoL for survivors was 0.74.
Annual initial inhospital treatment cost for all AUGIB
cases in the UK was estimated to be £155.5 million,
with exploratory analyses of the incremental costs of
treating hospitalised patients developing AUGIB
generating figures of between £143 million and £168
million.
Conclusions: AUGIB is a large burden for UK
hospitals with inpatient stay, endoscopy and RBC
transfusions as the main cost drivers. It is anticipated
that this work will enable quantification of the impact of
cost reduction strategies in AUGIB and will inform
economic analyses of novel or existing interventions for
AUGIB.
Trial registration number: ISRCTN85757829 and
NCT02105532.
Strengths and limitations of this study
▪ Acute upper gastrointestinal bleeding (AUGIB) is a
common medical emergency often requiring inten-
sive investigation and treatment, yet little is known
about associated healthcare costs. This paper
reports the largest prospective micro-costing study
to date of patients presenting to hospital with a first
AUGIB, and provides estimates of patient-level
healthcare costs and health-related quality of life
(HRQoL). Additionally, the indirect cost impact of
AUGIB beyond the healthcare sector is explored for
the first time.
▪ The average cost of initial in-hospital treatment is
estimated to be £2458 (SE £216) per patient.
Applying these cost estimates to national inci-
dence figures for all AUGIB cases (those present-
ing to hospital (84%) and those already in
hospital (16%)) suggests the annual cost of
initial in-hospital treatment in the UK could be
£155.5 million. Uncertainty around the treatment
costs for already hospitalised patients developing
AUGIB is explored using sensitivity analysis.
▪ By day 28 post-AUGIB, one-third of patients had
received an average of 9 days of unpaid care and
one-quarter who were in paid employment had lost
an average of 11.6 working days. These findings
should be interpreted with caution as data were
missing for over 40% of the surviving study patients
who appeared to have fewer comorbidities than
patients who responded to the questions. HRQoL
was impaired at day 28 post-AUGIB discharge.
▪ It is anticipated that by providing information on
the key cost drivers associated with AUGIB, this
work will enable healthcare providers to identify
avenues for cost reduction in AUGIB as well as
provide a point of reference for cost-effectiveness
research.
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INTRODUCTION
Acute upper gastrointestinal bleeding (AUGIB) is a
common medical emergency, and a major cause of mor-
bidity and mortality in western populations. Its incidence
is estimated to be between 100 and 200 cases per
100 000 resulting in over 50 000 admissions annually to
UK hospitals.1 During hospitalisation, AUGIB frequently
results in intensive medical investigation and treatments
including laboratory tests, transfusion, and diagnostic
and therapeutic strategies to identify and control bleed-
ing such as endoscopy, radiological embolisation and
sometimes surgery. Thus, it is likely to impose a substan-
tial burden on healthcare resources although, to date,
this has been poorly characterised as outlined in a sys-
tematic review.2 Additionally, little is known about the
indirect cost impact of AUGIB beyond the healthcare
sector or health-related quality of life (HRQoL) experi-
enced by patients following the event.
This paper reports the largest prospective micro-
costing study of patients with AUGIB to date. For the
first time, costs both within and beyond the health and
social care sector are considered, along with data on
patient HRQoL. As part of a randomised trial of red
blood cell (RBC) transfusion strategies for AUGIB, we
conducted a nested, prospective evaluation of health
and social care resource use and costs, unpaid informal
care provided to patients by relatives and/or friends,
time away from paid employment (productivity losses),
and patient HRQoL with the following objectives:
1. To generate an inventory and costing of in-hospital
resources utilised by patients presenting to hospital
with AUGIB;
2. To explore the range of costs (healthcare, social care,
informal care and employers) incurred postdischarge
up to 28 days; and
3. To determine levels of HRQoL at day 28 and deter-
minants of these levels.
METHODS
TRIGGER (transfusion in gastrointestinal bleeding;
ISRCTN 85757829 and ClinicalTrials.gov NCT02105532)
was a multicentre, pragmatic, cluster randomised trial of
restrictive versus liberal RBC transfusion strategies for
AUGIB. The trial protocol has previously been pub-
lished.3 4 In brief, the aim of the trial was to evaluate the
feasibility and safety of implementing a restrictive versus
liberal RBC transfusion policy for adult patients admit-
ted to hospital with AUGIB. Six hospitals in the UK took
part (in Edinburgh, Glasgow, Leeds, Middlesbrough,
Nottingham and Oxford) and recruited 936 patients
between August 2012 and March 2013.5 Three hospitals
were randomised to the liberal transfusion policy (n=533
patients) and three to the restrictive policy (n=403
patients). The time horizon for the trial was 28 days and
the transfusion policy at each institution was maintained
for the duration of a patient’s index hospital admission
up to a maximum of 28 days. As TRIGGER was a
feasibility trial intended to inform the design of a subse-
quent definitive trial incorporating a full cost-
effectiveness analysis, a formal comparison of resource
use and costs between trial arms was not planned.
In-hospital resource use data collection and costs
Case record forms were designed to capture in-hospital
resource use during the index admission for each trial
patient and were completed by research staff at each
hospital site using patient case notes, drug charts and
electronic hospital records. Resource use data recorded
included all laboratory tests, medications, intravenous
fluids in the first 24 h and all blood component transfu-
sions. Data were also collected on the number of endos-
copies performed (diagnostic and therapeutic), use of
surgery or radiological intervention to control bleeding
and all adverse events. Full definitions of all trial end
points are provided in the protocol.3 4 To map each
patient’s journey between clinical areas in the hospital,
research staff also recorded admission and discharge
dates and times for relevant clinical areas including the
emergency department (ED), medical admissions unit,
the intensive treatment unit, high dependency unit,
endoscopy suite and general medical/surgical wards.
Unit costs (UK £2012/13) for each in-hospital
resource use component were obtained from several
national sources including the National Health Service
(NHS) Reference Costs, NHS Blood and Transplant
Price List, NHS Electronic Market Information Tool and
the Personal and Social Services Research Unit
(PSSRU).6–9 Unit costs used and their sources are shown
in online supplementary appendix table A1. For each
patient, the amount of each type of resource consumed
or event occurring was multiplied by its associated unit
cost to estimate the total cost of that resource or event.
Blood products were costed to include the cost to the
hospital transfusion laboratory of issuing each compo-
nent. Nursing time associated with administering com-
ponents was already included in the bed day unit costs
used to cost inpatient length of stay and so was not
costed separately. NHS Reference Costs provided a unit
cost for each type of endoscopy performed and the
common adverse events reported, but already included
the cost of the hospital stay. Bed days were costed separ-
ately in this study and so the proportion of each unit
cost that was attributable to bed days was estimated and
removed in order to avoid double counting. Details of
how all individual resource use items were costed are
provided in the online web appendix.
Postdischarge resource use and costs
At day 28, patients who were discharged from hospital
and still alive were interviewed by telephone about
health and social care contacts since discharge. Contacts
included readmissions to hospital (acute and community
hospitals), admissions to nursing homes/residential
care, contacts with the hospital ED, outpatient clinics,
day hospitals, general practitioners (GPs), nurses and
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any other health or social care provider. The full range
of unit costs used to value these contacts is shown in
online supplementary appendix table A1. Patients were
also asked whether they had received unpaid informal
care from family and/or friends since leaving hospital.
Shadow pricing was used to cost this time by multiplying
the number of hours of care provided by an informal
care cost per hour which was estimated by dividing gross
national average weekly wage rates (averaged across
males and females—see online supplementary appendix
table A1) by national average weekly working hours.10
This approach assumes that the value of the time given
up by individuals to provide unpaid informal care (or
the opportunity cost of this time) is adequately reflected
by the working wage.
In addition, information was sought on employment
status and hours worked prior to the index hospital
admission, whether patients had subsequently returned
to work, and if so, how many hours they were currently
working. For each patient who had not been able to
return to work, weekly working hours lost during the
28-day trial period were calculated. This time was costed
using gross national average weekly wage rates. For
patients returning to work (including at reduced hours),
working hours lost were also calculated and costed.
Health-related quality of life
At day 28 patients completed the three-level EuroQol
EQ-5D questionnaire which measures generic HRQoL
and contains questions on five dimensions: mobility, self-
care, usual activities, pain and discomfort, and anxiety
and depression.11 Responses to the EQ-5D were con-
verted into a single index score on a scale where 0 repre-
sents dead and 1 represents full health using a tariff
estimated by using data from the UK general
population.12 13
Statistical analysis
The proportion of patients with missing data was
reported for each resource use variable and for the
EuroQol EQ-5D questionnaire. Missing data were
assumed to be missing at random and multiple imput-
ation (MI) with chained regression equations was used
to impute missing health and social care resource use
values and EQ-5D HRQoL scores.14 Individual regres-
sions were specified for each variable with missing data
and five values were imputed for each missing data cell.
Rubin’s Rule was used when summarising data across
the five data sets created using MI.15
Owing to the cluster randomisation, multilevel linear
regression modelling was used to adjust health and
social care resource use, costs and HRQoL estimates for
variability between centres (specifically, a random inter-
cept for centre was used).16 17 Rather than averaging
across all patients as though they were drawn from a
single population, multilevel modelling acknowledges
the hierarchical nature of the data, that is, that patients
are recruited from different centres and have the
potential to be more similar to other patients from the
same centre than to those between centres. Continuous
resource use variables and costs were expressed as
means, and SEs and categorical variables as percentages.
National costs
Using UK population figures and reported data on the
incidence of AUGIB, an estimate was made of the
annual total number of cases of AUGIB in the UK by
age bands.18 19 Multiplying these figures by the (age-
specific) mean estimates of initial in-hospital costs per
patient estimated by this study allowed calculations to be
made of the potential initial hospital treatment costs of
AUGIB in the UK. It is acknowledged that around 16%
of national AUGIB cases will likely manifest in patients
already in hospital for another condition, but that the
incremental cost of treating a bleed in these patients is
unclear (the TRIGGER trial included only new presenta-
tions to hospital).20 While the analysis above assumes no
difference in treatment costs for patients presenting to
hospital and patients already resident in hospital, a
series of alternative scenarios were explored whereby the
mean per patient cost estimates were assumed to be
50% higher; this was 50% lower for the estimated 16%
of total cases already in hospital. All analyses were per-
formed using STATA V.12 (StataCorp, College Station,
Texas, USA).
RESULTS
Baseline demographics data are shown in table 1. The
mean (SD) age of patients was 59.4 (20.1) years and
60.5% were male. Mean Rockall and Blatchford Scores
were 2.3 (1.9) and 6.0 (4.6), respectively. In just over a
fifth of patients bleeding was attributed to peptic ulcer,
in a quarter to oesophagitis/gastritis/duodenitis, and in
12% to varices. Thirty-two (3.4%) patients died during
the index hospital admission and 42 (4.5%) patients
had died by day 28.
In-hospital resource use and costs
Data completeness for in-hospital resource use was
98.6%. On average patients were transfused 1.58 (SE
0.20) units of RBCs (table 2). One-quarter of patients
received therapeutic endoscopy. Only a small proportion
of patients underwent surgical (1.3%) or radiological
(1.3%) interventions to control bleeding. Serious
adverse events were infrequent (ranging from 0% for
deep vein thrombosis to 1.8% for acute kidney injury).
Mean overall length of hospital inpatient stay was 5.34
(0.29) days. Mean (SE) total in-hospital costs across all
trial patients were estimated to be £2458 (£216), with
almost 60% of this cost attributable to inpatient bed days
(£1439 (£111)), 26% to diagnostic and therapeutic
endoscopies (£642 (£71)) and 8% to RBC transfusion
(£198 (£25)) (table 2).
The total annual initial in-hospital treatment costs
for AUGIB in the UK were estimated at £155 437 055
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(table 3). Costs increased with age, ranging from a mean
cost of £1143 for patients aged less than 29 years to £3190
for patients over 75 years. Assuming that inpatient treat-
ment costs for the 16% of all patients with AUGIB likely
to experience a bleed while already in hospital for
another condition were 50% higher and 50% lower than
the costs observed here generated national cost estimates
of £168 million and £143 million, respectively.
Postdischarge health and social services resource use and
costs
For postdischarge resource use and costs up to 28 days,
33% of data were missing. Two hundred and sixty-six
(30%) of the 894 patients, not recorded as having died by
28 days, were missing data on all postdischarge health and
social care contacts. Non-responding patients were signifi-
cantly younger than responders, were more likely to have
presented with shock but were less likely to have had
comorbidities, and had lower Blatchford Scores and
higher presenting haemoglobin levels (see columns 3 and
4 of table 1).
The mean (SE) number of acute hospital readmission
bed days was 0.52 (0.08) per patient (table 2). The
mean (SE) number of outpatient clinic visits was 0.41
(0.06) and the mean number of GP visits was 0.65
(0.06). In total, postdischarge health and social care
costs up to 28 days averaged £391 (£44) per patient.
Acute hospital readmissions accounted for 36% of this
total cost (£139 (£21)); day hospital, clinic and ED visits
for 28% (£109 (£16)); and primary/social care contacts
for 24% (£93 (£23)).
Total health and social care costs (in-hospital and
postdischarge to 28 days)
Mean (SE) total health and social care costs from hos-
pital presentation up to 28 days were £2851 (£225) per
patient (table 2).
Table 1 Patient demographics and mortality for whole cohort and for patients providing and not providing data at 28 days
Characteristics and mortality
Whole
cohort
n=936
Patients not recorded as having died at 28 days
n=894
Data provided on
health and social care
contacts at 28 days
n=628
No data provided on
health and social care
contacts at 28 days
n=266 p Value*
Male—n (%) 566 (60.5) 372 (59.2) 170 (63.9) 0.191
Age (years)—mean (SD) 59.4 (20.1) 60.5 (19.4) 54.0 (20.8) <0.01
Rockall Score—mean (SD) 2.3 (1.9)† 2.3 (1.9) 2.1 (1.9)† 0.162
Blatchford Score—mean (SD) 6.0 (4.6)‡ 6.1 (4.6)§ 5.2 (4.4)¶ <0.01
Shock at presentation—n (%) 221 (23.7)¶ 133 (21.2)** 78 (29.3)† 0.031
Haemoglobin (g/dL) at first measurement—
mean (SD)
11.6 (3.3) 11.5 (3.3) 12.3 (3.2) <0.01
Pre-existing comorbidities—n (%)
Ischaemic heart disease 137 (14.6) 94 (15.0) 33 (12.4) 0.316
Cardiac failure 39 (4.2)† 26 (4.1)† 7 (2.6) 0.446
Hypertension 232 (24.8)† 162 (25.8)† 47 (17.7) 0.025
Respiratory disease 158 (16.9)† 112 (17.8)† 37 (13.9) 0.283
Renal disease 54 (5.8) 45 (7.2) 8 (3.0) 0.016
Liver disease 136 (14.5) 93 (14.8) 30 (11.3) 0.161
Cancer/malignancy 99 (10.6)† 61 (9.7)† 25 (9.4) 0.800
Source of bleeding—n (%)††
Peptic ulcer 153 (22.7) 97 (21.0) 50 (27.5) 0.080
Gastro-oesophageal varix 81 (12.0) 56 (12.1) 18 (9.9) 0.419
Oesophagitis/gastritis/duodenitis 171 (25.4) 116 (25.2) 49 (26.9) 0.645
Mallory-Weiss tear 30 (4.5) 21 (4.6) 95 (4.9) 0.833
Malignancy 22 (3.3) 13 (2.8) 7 (3.8) 0.500
Non-identified 109 (16.2) 81 (17.6) 25 (13.7) 0.238
Other 107 (15.9) 77 (16.7) 24 (13.2) 0.270
All-cause mortality—n (%)
In-hospital 32 (3.4) – – –
28-day 42 (4.5) – – –
*Based on χ2 for categorical variables and t test for continuous variables.
†Missing for one patient.
‡Missing for seven patients.
§Missing for four patients.
¶Missing for three patients.
**Missing for two patients.
††Not recorded for 263 patients.
4 Campbell HE, et al. BMJ Open 2015;5:e007230. doi:10.1136/bmjopen-2014-007230
Open Access
 o
n
 5 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2014-007230 on 29 April 2015. Downloaded from 
Table 2 Total and mean per patient healthcare resource use and cost (UK £2012/13) for the cohort
Resource use
Total resource
consumption
across cohort*
Resource use
Mean (SE) per patient or
per cent of cohort
with procedure/event
Cost
Mean (SE) per patient
across whole cohort
n=936 n=936 n=936
In-hospital episode
Blood products†
RBC units 1478 1.58 (0.20) £198.13 (£24.55)
FFP units 174 0.19 (0.05) £5.72 (£1.35)
Platelets units 61 0.07 (0.02) £13.84 (£3.97)
Cryoprecipitate units 12 0.01 (0.01) £2.45 (£1.53)
Single factor VIIa dose 2 0.25% £2.55 (£46.86)
Laboratory testing‡
FBC tests 4592 4.88 (0.26) £16.47 (£0.87)
Urea and electrolytes tests 4266 4.52 (0.31) £5.74 (£0.39)
Liver function tests 3081 3.29 (0.44) £2.27 (£0.30)
Coagulation tests 2406 2.55 (0.30) £17.22 (£2.06)
Medications§
Medications Various¶ Various¶ £23.76 (£5.59)
Fluids in 24 h**
Colloids (L) 117 0.12 (0.04) £0.63 (£0.23)
Crystalloids (L) 1606 1.72 (0.07) £2.44 (£0.10)
Endoscopies††
Diagnostic 506 0.57 (0.06) £371.13 (£36.24)
Therapeutic 277 0.29 (0.05) £270.40 (£44.83)
Interventions‡‡
Surgical 12 1.3% £19.37 (£5.56)
Radiological 12 1.3% £33.42 (£16.14)
Adverse events in hospital‡‡
Acute coronary syndrome 4 0.4% £3.77 (£1.88)
Stroke 3 0.3% £4.77 (£2.75)
Acute kidney injury 17 1.8% £27.69 (£8.79)
Pulmonary embolism 5 0.5% £4.01 (£1.79)
Deep vein thrombosis 0 0% £0.00 (£0.00)
Length of hospital stay
Total length of hospital stay (days) 4997 5.34 (0.29) £1438.97 (£110.86)
Total in-hospital costs – £2457.58 (£215.73)
Postdischarge care§§,¶¶,***
Acute hospital readmission bed days 490 0.52 (0.08) £138.96 (£20.75)
Community hospital admission bed days 66 0.07 (0.04) £18.80 (£10.62)
Nursing/residential care admission bed days 367 0.38 (0.20) £32.05 (£17.12)
Number of ED visits 160 0.17 (0.03) £17.33 (£2.56)
Number of hospital clinic visits 374 0.41 (0.06) £50.42 (£6.93)
Number of day hospital visits 87 0.10 (0.03) £41.22 (£11.37)
Number of visits to GP 608 0.65 (0.06) £29.44 (£2.72)
Number of GP home visits 98 0.10 (0.02) £11.88 (£2.01)
Number of visits to practice nurse 183 0.20 (0.03) £2.67 (£0.42)
Number of home visits from district nurse 313 0.34 (0.09) £13.44 (£3.42)
Number of other health/social visits 700 0.77 (0.48) £35.00 (£21.99)
Total postdischarge costs to 28 days – – £391.20 (£43.55)
Total costs to 28 days – – £2850.85 (£225.15)
*Based on data following multiple imputation.
Data were missing and therefore imputed on:
†RBCs for 1 patient/FFP, platelets and cryoprecipitate for 10 patients/rFVIIa for 37 patients.
‡Laboratory tests for seven patients.
§Medications for 56 patients.
¶Numerous and so not reported individually.
Data were missing and therefore imputed on:
**Colloids for 39 patients/crystalloids for 32 patients.
††Diagnostic and therapeutic endoscopies for 12 patients.
‡‡Surgical intervention, radiological intervention, acute coronary syndrome, stroke, acute kidney injury, pulmonary embolism and deep vein
thrombosis for one patient.
§§Denominator when estimating missing data for postdischarge care is 894 patients not recorded as having died by 28 days.
¶¶Data missing on acute hospital readmission for 272 patients/community hospital readmissions and nursing home and residential care
admissions for 304 patients/ED visits for 278 patients/hospital clinic visits for 275 patients/day hospital visits for 276 patients/GP visits, GP
home visits, practice nurse visits and district nurse home visits for 315 patients/other health and social care visits for 398 patients.
***Data reported are total number of bed days and visits with some patients having numerous contacts.
ED, emergency department; FBC, full blood count; FFP, fresh frozen plasma; GP, general practitioner; RBC, red blood cell.
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Non-health and social care costs—unpaid informal care
and productivity losses
At day 28, of the 894 patients not recorded as having
died, 523 (59%) provided information on unpaid infor-
mal care and 526 (59%) on time away from paid
employment.
Approximately one-third (180/523, 34%) of patients
reported having received unpaid informal care from a
relative or friend after leaving hospital. Table 4 shows that
over the trial period, these patients received a mean (SE)
of 69 (10) hours of unpaid care which is equivalent to
around 9 (7.5 h) working days. Cost estimates for this time
were averaged across all patients completing the questions
(n=523) which produced a mean (SE) cost of £357 (£88).
Approximately 23% (123/526) of patients reported
that they had been in paid employment prior to present-
ing to hospital with AUGIB. Table 4 shows 34% (41/121)
of these patients reported that they had not been able to
return to work; mean working hours lost in this group
were estimated to be 125 (or around 17 working days)
per patient. Of the 66% (80/121) patients who were able
to return to work, a mean of 66 working hours
(9 working days) were lost due to absence and reduced
working hours. Average working time lost across all
patients who had been in paid employment was
11.6 days. Costing time away from the workplace (absence
and reduced hours) and averaging across all patients
completing the questions (n=526) estimated productivity
losses to be £275 (£27) per patient.
Health-related quality of life
EQ-5D data were missing for 390/936 (42%) patients
as telephone contact at day 28 could not be made. Of
the surviving patients with data, over 40% reported
Table 3 Estimate of annual initial hospital costs for acute upper gastrointestinal bleeding (AUGIB) in the UK
Age bands
(years) UK Population*
AUGIB incidence
per 100 000/year†
Annual number of
patients with AUGIB
in UK population
Mean total initial
hospital cost
estimates‡
Annual
total costs
16–29 11 806 800 23 2716 £1143 (n=91) £3 104 535
30–44 12 843 400 41 5266 £2053 (n=150) £10 811 709
45–59 12 605 800 69 8698 £2183 (n=224) £18 990 830
60–64 3 624 400 109 3951 £2686 (n=78) £10 613 733
65–74 5 820 900 214 12 457 £2749 (n=142) £34 248 977
75+ 5 020 000 485 24 347 £3190 (n=251) £77 667 271
Total 51 721 300 – 57 434 – £155 437 055
*Data on population from Office for National Statistics 2012.19
†AUGIB incidence figures taken from Rockall et al.18
‡Mean cost estimates based on analysis of TRIGGER data reported in this paper.
Table 4 Reported data on unpaid informal care and productivity costs at 28 days
n (%) Missing data
n=894* Reported data
Unpaid informal care 371 (41.5%) n=523
Receiving any unpaid informal care—n (%) 180/523 (34.4%)
Hours of unpaid informal care if received—mean (SE)
n=180
69.17 (10.3)†
Total cost of unpaid informal care
n=523
£357.30 (£88.16)‡
Employment status 368 (41.2%) n=526
In paid employment before admission—n (%) 123/526 (23.4%)
Not returned to work since admission—n (%) 41/121 (33.9%)§
Hours of work lost if not returned—mean (SE)
n=41
125.21 (7.8)¶
Returned to work since admission—n (%) 80/121 (66.1%)§
Hours of work lost if returned to work—mean (SE)
n=80
66.30 (5.5)**
Total cost of lost working hours—mean (SE) £274.58 (£26.50)††
Italics typeface are used for average hours within each section.
*n=894 patients not recorded as having died at 28 days.
†Mean imputation used for hours of informal care missing for 32/180 patients.
‡Costs of informal care adjusted for clustering and averaged across all 523 patients.
§Return to work field missing for 2/123 patients.
¶Mean imputation used for hours of lost work time data missing for 1/41 patients who were known not to have returned to work.
**Mean imputation used for hours lost data missing for 7/80 patients who were known to have returned to work.
††Productivity costs adjusted for clustering and averaged across all 526 patients.
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having some problems (level 2) with mobility and over
30% reported some problems with usual activities, pain
and discomfort, and anxiety and depression (figure 1).
The mean (SE) EQ-5D HRQoL score at 28 days across
the cohort (assigning a zero score to patients who had
died) was 0.683 (0.01); MI and adjustment for clustering
of this value increased it to 0.701 (0.02). For surviving
patients the mean score was 0.735 (0.02). By compari-
son, the mean EQ-5D score for the UK general popula-
tion has previously been reported to be 0.86.21
DISCUSSION
This study has explored resource use and cost implications
for patients presenting to hospital with AUGIB for the
NHS and social services up to 28 days postpresentation.
Mean in-hospital costs were estimated to be £2458 (SE
£216) per patient; 60% of this cost was attributable to
inpatient bed days, 26% to endoscopy and 8% to RBCs.
Local NHS Hospital Trusts may find it useful to compare
their own average reimbursement figures for patients with
AUGIB to these cost estimates. Costs of health and social
care contacts beyond hospital discharge up to 28 days sug-
gested further costs of £391 (SE £44) per patient.
Combining data from this study with UK population
figures and estimates of AUGIB incidence, the total
annual UK cost of initial hospital treatment was esti-
mated to be £155.5 million with just over £93 million
(60%) of this cost attributable to in-hospital length of
stay, £38.5 million (25%) to endoscopy and £12.6
million (8%) to RBCs. This amounts to approximately
0.13% of total NHS spending (£120 billion in England,
Scotland, Wales and Northern Ireland in 2010/2011).22
The reliability of these figures rests on a number of
study parameters, perhaps most important of which is
whether the patients in this study are representative of
all patients with AUGIB presenting to hospital. A com-
parison of study patients with admissions to hospital in
the 2007 UK audit of AUGIB (a cross-sectional audit of
208 UK hospitals) suggests similar mean ages (59.4 vs
62.6 years), gender (60.5% male vs 60% male), median
presenting haemoglobin (11.9 vs 11.4 g/dL), median
Rockall Score (2 vs 2), aetiology of bleeding and median
hospital stay (4 vs 5 days).20 In-hospital mortality for new
presentations in the 2007 audit, however, was double
that observed in the TRIGGER trial (6.8% vs 3.4%).
This observation may be attributable to a number of
reasons: first, TRIGGER excluded patients with exsan-
guinating bleeding, a group associated with greater mor-
tality; and second, improvements in care, namely, better
access to emergency endoscopy than that was present in
the nationwide audit in 2007. It must also be acknowl-
edged that the incidence figures for AUGIB in the UK
used in this study when estimating national costs include
a proportion (16%) of patients already hospitalised
when developing a bleed. Although the incremental cost
of treatment for these patients was not calculated here
(the TRIGGER trial included only patients presenting to
hospital), analyses assuming costs for this subgroup of
patients were 50% higher and 50% lower than those
observed here, altered the national cost estimates by
just 8%.
Figure 1 Distribution of patient responses across levels for each of the five EQ-5D domains. ▪ Level 1—no problems; ▪ level 2
—some problems; ▪ level 3—extreme problems.
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Knowledge of key cost drivers in the treatment of
AUGIB can enable healthcare providers to identify
avenues for cost reduction and be a point of reference
for cost-effectiveness research. For example, a large UK
study has shown that more timely endoscopy for AUGIB
(<12 vs >12 h postpresentation) can reduce hospital
inpatient stay (shown here to be responsible for 60% of
in-hospital costs for this population) by an average of
1.7 days.23 Any cost savings brought about via a reduc-
tion in hospital stay would, however, need to be offset
against the cost of additional resources required to facili-
tate more rapid access to endoscopy and to be consid-
ered alongside any potential impact on patient
outcomes. Similarly, the TRIGGER feasibility trial
reported a trend towards improved safety with a restrict-
ive RBC transfusion policy and observed a reduction in
the mean number of RBC units transfused from 1.91
under a liberal policy to 1.21 (mean difference 0.7 units,
95% CI −1.6 to 0.3).5 Using these findings together with
the national cost estimates in table 3 and assuming that
half of the patients with AUGIB in the UK are already
exposed to a restrictive transfusion policy, changing prac-
tice for the remaining 50% of patients could potentially
save 20 102 units of RBCs, which at a cost of £123.31 per
unit amounts to savings of £2.48 million; however, even
this may be an underestimate because the percentage of
hospitals currently using a restrictive policy is likely to be
less than 50%. Furthermore, true cost savings will be
greater when the input of hospital transfusion laborator-
ies and nursing staff who issue and administer RBCs are
accounted for.
To the best of our knowledge, this is the first study to
explore the impact of AUGIB on costs beyond the
healthcare sector. The observation that just over a third
of patients contacted by telephone at day 28 reported
that they had received an average of 9 days of unpaid
informal care from family members and/or friends is
noteworthy, as is the finding that almost a quarter of
patients answering questions on employment status
reported that they were in paid employment prior to
their AUGIB and lost an average of 11.6 days of work as
a result of their condition. These data highlight the
importance of assessing the impact of new treatments
and interventions for AUGIB beyond the healthcare
sector.
Previous work in this area is limited. A systematic review
identified just seven studies reporting on healthcare
resource use and costs in AUGIB.2 Differences between
these studies and the work presented here in terms of jur-
isdiction (six of the seven studies identified were from
the USA or Canada), methodologies (all studies used
retrospective data collection with some using claims reim-
bursement data and possibly valuing resource use data
with charges rather than costs) and relevance to current
practice (the most recently published study analysed data
up to 2003 only and did not report a breakdown of
inpatient resource use) imply that a comparison across
studies is unlikely to be informative.
Few data have been reported on HRQoL in patients
with AUGIB. In 2007, Leontiadis et al24 administered the
EuroQol EQ-5D questionnaire to 57 patients surviving
an upper gastrointestinal bleed in two English hospitals
at 7 days postbleed or hospital discharge (whichever was
earlier), and at 4 weeks postbleed. A single index score
of 0.45 was reported at 7 days/hospital discharge and
0.78 at 4 weeks. This latter score is similar to the value of
0.735 seen for surviving patients in our study at the same
time point, although a limitation of our data is the lack
of information on baseline HRQoL at presentation. Our
larger sample size and the multicentre nature of the
study, conducted in geographically diverse units, does
enhance the generalisability of our results to broader
UK practice.
A number of uncertainties in the data presented
should be acknowledged. First, over 30% of patients had
no healthcare resource use follow-up data and over 40%
had no informal care, employment or HRQoL data.
Despite study research nurses attempting to contact each
patient by telephone, the difficulties encountered with
follow-up appear to be due at least in part to a combin-
ation of the cohort’s demographic and lifestyle factors, or
comorbidities. A comparison of responding and non-
responding patients suggested non-responders were
younger and in better health than responders, with lower
Blatchford Scores and fewer comorbidities. While a
number of these variables were included as predictors in
the models used to impute missing postdischarge health-
care resource use data, we chose not to impute informal
care costs and productivity losses given the magnitude of
the missing data issue. Even in spite of the uncertainty
surrounding these estimates, we believe inclusion of
these data still adds value to the paper for two main
reasons. First, our data have shown (perhaps unexpect-
edly) that despite an average age of almost 60 years, at
least a quarter of patients were still in paid employment
and lost time away from the workplace as a result of their
bleed (this percentage is likely to be even higher if the
younger healthier patients with missing data were also in
paid employment). In light of these findings it would,
therefore, be important for assessments of the cost-
effectiveness of interventions or policies for AUGIB to
seek the impact of both within and beyond the health-
care sector. Second (and again perhaps unexpectedly)
this study has shown that it appears to be younger health-
ier patients who are more difficult to contact posthospital
discharge. This observation may assist researchers follow-
ing this patient group in the future to develop tailored
data collection strategies, for example, combined use of
telephone contact and postal questionnaires for younger
patients who have presumably returned to work and
normal social activities.
Second, we costed the most common adverse events,
but noted that 90 patients were recorded as having at
least one ‘other’ adverse event during the course of the
trial. Events included sepsis, pneumonia, oedema,
seizure, advanced pancreatic cancer resulting in death
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and end-stage liver disease, etc. While any change in the
duration of the index hospital inpatient stay, medication,
laboratory tests and readmissions to hospital arising as a
consequence of such events would have been captured
by the trial, it was not possible to collect detailed infor-
mation on all treatments administered for such events,
and therefore, costs may be slightly underestimated.
Finally, analyses assumed cost data were normally dis-
tributed. While costs may be better analysed using gener-
alised gamma models (to handle skewness), it proved
difficult to run such models within the context of this
study given the need to deal with simultaneous issues of
missing data, clustering and high proportions of patients
with zero costs for many individual resource use items.
Other researchers have recently noted a lack of statistical
methods for dealing with these issues and have called
for further methodological studies to consider
approaches for use, particularly in trials with high pro-
portions of zero costs.25 Studies have shown that
methods assuming normality can be quite robust even
when costs are highly skewed; however, within this study
it is difficult to know whether the precision of cost esti-
mates would have improved had it been possible to esti-
mate an aggregated multilevel generalised gamma
model across MI data sets.17
CONCLUSIONS
This is the first study to quantify the healthcare costs
associated with AUGIB in the UK. Inpatient stay, endos-
copy and RBCs are key cost drivers. Costs of AUGIB
beyond the healthcare sector are likely to be consider-
able and should be considered in assessments of future
interventions for AUGIB. These data will assist health-
care agencies in interpreting the cost implications of
care processes for AUGIB and will help clinicians and
researchers to determine the economic impact of novel
and existing interventions for AUGIB.
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